SCHEMBL4860708

SCHEMBL4860708

O=C(O)C(Cc1ccccc1)NC(=O)N1CCCCc2ccccc21

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.54
HSD17B10 Q99714 1/20 0.54
TP53 P04637 1/20 0.53
POLB P06746 7/20 0.52
LMNA P02545 1/20 0.52
MAPT P10636 1/20 0.52
RECQL P46063 1/20 0.51
AVPR2 P30518 1/20 0.51
OXTR P30559 1/20 0.51
AVPR1A P37288 1/20 0.51
FPR2 P25090 1/20 0.49
THRB P10828 1/20 0.49
PTPN11 Q06124 1/20 0.49
PRMT5 O14744 1/20 0.48
WDR77 Q9BQA1 1/20 0.48
TSHR P16473 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
GRM7 Q14831 1/20 0.47
KMT2A Q03164 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4860714 1.00 ALDH1A1 (0.54) ALDH1A1HSD17B10TP53POLBLMNA
SCHEMBL18766740 0.96 POLB (0.55) ALDH1A1HSD17B10TP53POLBRECQL
SCHEMBL18766742 0.96 POLB (0.55) ALDH1A1HSD17B10TP53POLBRECQL
SCHEMBL4872524 0.89 ATM (0.56) TP53POLBLMNAMAPTTHRB
SCHEMBL4872519 0.89 ATM (0.56) TP53POLBLMNAMAPTTHRB
SCHEMBL4870223 0.88 TP53 (0.57) TP53POLBLMNAMAPTFPR2
SCHEMBL18766866 0.85 POLB (0.56) ALDH1A1POLBMAPTRECQLKMT2A
SCHEMBL18766868 0.85 POLB (0.56) ALDH1A1POLBMAPTRECQLKMT2A
SCHEMBL4868334 0.80 POLB (0.59) ALDH1A1TP53POLBLMNAMAPT
SCHEMBL4869484 0.80 FPR1 (0.47) TP53POLBLMNAMAPTAVPR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7368444-B2 N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2008-05-06 US disclosed
US-20050101600-A1 N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2005-05-12 US disclosed
EP-1475368-A1 N-CARBAMOYL NITROGEN-CONTAINING FUSED RING COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2004-11-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101600-A1 N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient CNR1, CNR2, NPSR1 ALDH1A1 3990/4885HSD17B10 1075/4885TP53 4170/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.